In the BioHarmony Drug Report Database

"Preview" Icon

Gemtuzumab ozogamicin

Mylotarg (gemtuzumab ozogamicin) is an antibody pharmaceutical. Gemtuzumab ozogamicin was first approved as Mylotarg on 2017-09-01. It is used to treat myeloid leukemia acute and myelomonocytic leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against myeloid cell surface antigen CD33.

 

Trade Name

 

Mylotarg
 

Common Name

 

gemtuzumab ozogamicin
 

ChEMBL ID

 

CHEMBL1201506
 

Indication

 

myeloid leukemia acute, myelomonocytic leukemia acute
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)

Image (chem structure or protein)

Gemtuzumab ozogamicin structure rendering